Selection of Synthetic VHHs - in vitro
Release time:
2023-04-16
Our optimized Phage Display selection technology delivers high quality and fully functional humanized recombinant nanobodies recognizing native antigens. Importantly, the structural integrity of the antigen is maintained throughout the entire VHH selection and validation process. Therefore, our nanobodies are more likely to recognize endogenous antigens for in vitro and in vivo applications, such as immunofluorescence, live cell imaging, protein degradation or blocking protein activity.
Key benefits
● Conformational antibodies
● Deliverables of the validated VHH binders include DNA sequences and plasmids
● Customized selection conditions (buffer, temperature, etc)
● Animal-free technology
Related News
2023-12-10
Targeting Protein-Protein Binding for Therapeutic Development: Unlocking the Potential of Biologics
2023-12-10
Understanding Protein Protein Binding and Its Significance in Medicine
2023-12-10
Understanding Protein Protein Binding: A Comprehensive Guide
2023-12-10
The Role of Protein Protein Binding in Drug Discovery: A Comprehensive Guide
2023-12-10
2023-12-09
Unveiling the Secrets of Protein-Protein Interaction: A Breakthrough Study
2023-12-09
2023-12-09